Navigation Links
Gleevec gets hopeful results

The Food and Drug Administration approved the drug, Gleevec, for the treatment of chronic myelogenous leukemia, a form of cancer that affects about 4,500 people in the USA each year. A study supports Gleevec's image as a potential cure for this kind of cancer, which, although cases are rare, can be deadly. //

A new study adds to the evidence suggesting that a heavily publicized drug treatment for a type of leukemia may allow patients to live longer than expected. Experts say the drug, made by Novartis Pharmaceuticals also holds promise for the treatment of lung cancer, prostate cancer and a form of stomach cancer.

In the longest study of the drug so far, researchers studied 532 patients with chronic leukemia. They all had received the standard drug, interferon, but after six months their cancer had gotten worse. The patients were switched to Gleevec, which they took once a day. After 18 months, the researchers could find no visible sign of the genetic abnormality that causes the disease in 41% of the patients.

That genetic flaw leads to the production of a protein that allows white cells in the blood and in the bone marrow to run out of control. Gleevec works by blocking the action of that protein.
'"/>




Page: 1

Related medicine news :

1. Gleevec for Lung Disease
2. "Miracle" Cancer Drug Gleevec Can be Toxic to the Heart
3. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
4. Artificial disc looks hopeful
5. Experimental treatment for Ebola Virus Shows promising results in mice
6. IVF results may be affected by stress and other related factors
7. New dosage of medicine gets more results in neuroblastoma
8. Caffeine can interfere with PET scan results
9. Mouth wash samples to predict bone marrow transplant results
10. PET scans can detect the results of cognitive behavior therapy
11. Induced abortion results in years of trauma.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... Order Custom ... new website. No need to be concerned about garment selection, expensive graphic ... where all orders are printed and shipped within 5-10 days. And every ...
(Date:9/25/2017)... ... September 25, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that two of its leading biologics ... at two upcoming conferences. , At the BEBPA 10th Annual Bioassay Conference, to ...
(Date:9/25/2017)... ... 25, 2017 , ... NCPDP Foundation , a 501(c)(3) ... awarded a $40,000 grant to Johns Hopkins Medicine to address patient safety risk ... to electronically cancel a prescription already submitted to a pharmacy. Studies indicate that ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... science and technology-enabled services supporting clinical research, today announces that 30 of ... aspects of the drug development lifecycle at upcoming industry conferences and webinars. ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:9/1/2017)...  Explorers Like Us ( https://explorerslikeus.com/ ) is embarking on ... and deliver these experiences as part of Life Environments™, a ... heal better. ... While nothing beats a walk, jog or simply playing in ... is the next best thing when getting there isn’t possible. ...
Breaking Medicine Technology: